Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Epicardial Adipose Tissue in HFpEF
NCT06510270Not yet recruiting
- Sponsor
- Aswan University
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
Open-label trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Aswan University. Primary endpoint: Reduction in Epicardial adipose tissue volume at 6 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06510270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510270.